Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Avidity Partners Management LP

Avidity Partners Management LP lessened its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 1.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,873,000 shares of the company's stock after selling 44,231 shares during the period. Dianthus Therapeutics accounts for about 6.2% of Avidity Partners Management LP's portfolio, making the stock its largest position. Avidity Partners Management LP owned approximately 9.71% of Dianthus Therapeutics worth $62,631,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Dianthus Therapeutics during the fourth quarter worth approximately $26,000. KLP Kapitalforvaltning AS bought a new position in shares of Dianthus Therapeutics in the fourth quarter valued at $33,000. KBC Group NV acquired a new position in shares of Dianthus Therapeutics during the fourth quarter valued at about $35,000. BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $59,000. Finally, AlphaQuest LLC raised its holdings in shares of Dianthus Therapeutics by 273.1% in the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock worth $91,000 after acquiring an additional 3,072 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $21.70 on Friday. The firm has a 50 day simple moving average of $19.85 and a 200 day simple moving average of $22.68. Dianthus Therapeutics, Inc. has a 1-year low of $13.37 and a 1-year high of $32.27. The firm has a market capitalization of $697.13 million, a price-to-earnings ratio of -8.68 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DNTH. Guggenheim reaffirmed a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $54.33.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.